Stockreport

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core o [Read more]